Latest Research And Development Funding News

Identitii Limited has locked in a $0.6 million R&D loan facility to bolster its growth amid rising BNDRY platform sales, supported by an expected $0.8 million R&D rebate and a $2.9 million Rights Issue.

Papyrus Australia reported a $112k net operating cash outflow in October 2025, offset by financing activities and R&D tax incentives, maintaining a runway of over five months. Despite a non-recurring legal expense and an investment write-down, the company remains confident in its operational continuity.

Island Pharmaceuticals has completed its acquisition of the broad-spectrum antiviral Galidesivir ahead of schedule, setting sights on expedited FDA approval leveraging the Animal Rule.

Island Pharmaceuticals has accelerated its acquisition of the Galidesivir antiviral program from BioCryst Pharmaceuticals, adding a clinically advanced asset with significant US government backing and a promising regulatory pathway.

Papyrus Australia reported a modest net operating cash outflow of $39,000 for May 2025, maintaining a solid cash position supported by available loan facilities that extend its funding runway to over 16 months.

Papyrus Australia reported a $52,000 operating cash outflow for April 2025 but bolstered its liquidity with $239,000 in financing inflows, extending its funding runway to over a year.

Bio-Gene Technology Limited has advanced its bio-insecticide pipeline with two U.S. Department of Defense grants totaling A$3 million, alongside key regulatory and production milestones for Flavocide® and Qcide®.